Core Insights - Neuronetics, Inc. has announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, marking a significant advancement in treatment accessibility for this demographic [1][2][3] Company Overview - Neuronetics, Inc. specializes in medical technology aimed at improving the quality of life for patients with neurohealth disorders, particularly through its NeuroStar Advanced Therapy [1][5] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for treating major depressive disorder (MDD) and other mental health conditions across the United States [5] Industry Context - TRICARE coverage is primarily utilized by active and retired military personnel and their families, with the new policy affecting beneficiaries in 26 states [2] - An estimated 4.3 million U.S. adolescents aged 15-21 are affected by major depression, highlighting the need for effective treatment options [3] - NeuroStar TMS therapy is recognized as a safe and effective first-line treatment for adolescents with major depressive disorder, especially given the limited medication options available [3][6] Treatment Efficacy - NeuroStar Advanced Therapy has delivered over 7.9 million treatments and is supported by the largest clinical data set for TMS treatment of depression [5] - The therapy is FDA-cleared for various indications, including as a first-line adjunct treatment for adolescents aged 15-21 with MDD [6]

Core Insights - Neuronetics, Inc. plans to release its third quarter 2025 financial and operating results on November 4, 2025, before market open, followed by a conference call at 8:30 a.m. Eastern Time [1] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology, particularly the NeuroStar® Advanced Therapy, which is a leading provider of Transcranial Magnetic Stimulation (TMS) [3] - The company operates Greenbrook TMS Inc. treatment centers across the U.S., offering NeuroStar Advanced Therapy for Major Depressive Disorder (MDD) and other mental health conditions [3] - NeuroStar Advanced Therapy has delivered over 7.6 million treatments and is supported by the largest clinical data set for TMS treatments for depression, including the world's largest depression outcomes registry [3] Treatment Offerings - NeuroStar Advanced Therapy is FDA-cleared for adults with MDD and is also indicated for adolescents aged 15-21 as an adjunct treatment [4] - Greenbrook treatment centers provide SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression (TRD) and for adults with MDD exhibiting acute suicidal ideation [3][4] - Greenbrook has administered over 1.8 million treatments to more than 55,000 patients suffering from depression [3]

Core Points - New York State Medicaid will cover Transcranial Magnetic Stimulation (TMS) services for adults diagnosed with major depressive disorder (MDD) starting October 1, 2025, for fee-for-service members and November 1, 2025, for those in Managed Care Plans [1][2] - This policy change will benefit nearly 1 million individuals with fee-for-service Medicaid and over 4.4 million individuals with Managed Care Organizations in New York [2] - Major depressive disorder affects 21 million adults in the U.S., with 6.4 million unable to tolerate or receiving inadequate relief from antidepressants [3] Company Overview - Neuronetics, Inc. is a medical technology company focused on neurohealth disorders and is the maker of NeuroStar Advanced Therapy, the leading provider of TMS [1][5] - NeuroStar Advanced Therapy is a non-drug, non-invasive treatment that has shown an 83% response rate and a 62% remission rate for MDD patients [3] - Neuronetics operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Advanced Therapy and has delivered over 7.6 million treatments [5] Industry Context - The decision by New York State Medicaid reflects a growing recognition of TMS as an evidence-based treatment for depression [2] - Neuronetics is the only TMS company with a dedicated health policy team advocating for health policy updates [4] - The NeuroStar Advanced Therapy System is FDA-cleared for various indications, including MDD and anxiety symptoms in adults [6]

Company Overview - Neuronetics, Inc. is a vertically integrated medical technology and healthcare company focused on transforming patients' lives through neurohealth therapies [1][3] - The company operates Greenbrook TMS Inc., which runs treatment centers across the U.S. offering NeuroStar Advanced Therapy for mental health disorders [3] Product and Treatment Information - NeuroStar Advanced Therapy is a non-drug, noninvasive treatment for major depressive disorder (MDD) and has delivered over 7.4 million treatments, supported by the largest clinical data set for TMS treatment systems [3] - Greenbrook treatment centers have provided more than 1.8 million treatments to over 55,000 patients suffering from depression, also offering SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression [3] Regulatory and Safety Information - The NeuroStar Advanced Therapy System is FDA-cleared for adults with MDD and as an adjunct treatment for obsessive-compulsive disorder and anxiety symptoms in adults with MDD [4]

Core Insights - Neuronetics, Inc. plans to release its second quarter 2025 financial and operating results on August 5, 2025, prior to market open [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results [1][2] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology [3] - The company is a leader in neuroscience, offering the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for mental health conditions [3] - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults with Major Depressive Disorder (MDD) who have not responded to previous antidepressant treatments [3] - The therapy is also FDA-cleared for use as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [3] - Over 7.1 million NeuroStar treatments have been delivered, establishing it as the leading Transcranial Magnetic Stimulation (TMS) treatment for MDD in adults [3]

Core Insights - Neuronetics, Inc. plans to release its first quarter 2025 financial and operating results on May 6, 2025, prior to market open [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results [1][2] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology [3] - The company is a leader in neuroscience, offering the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for mental health conditions [3] - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults with Major Depressive Disorder (MDD) who have not responded to previous antidepressant treatments [3] - The therapy is also FDA-cleared for use as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [3] - Over 7.1 million NeuroStar treatments have been delivered, establishing it as the leading Transcranial Magnetic Stimulation (TMS) treatment for MDD in adults [3]